Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 188Lymphoma, Mantle-Cell 34Neoplasms, Plasma Cell 32Lymphoma 32Recurrence 26Lymphoma, Follicular 20Waldenstrom Macroglobulinemia 18Lymphoma, Non-Hodgkin 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Carcinoma, Non-Small-Cell Lung 13Immunoglobulin Light-chain Amyloidosis 10Neoplasms 9Leukemia, Myeloid, Acute 9Lymphoma, B-Cell 8Renal Insufficiency 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Hodgkin Disease 6Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Prostatic Neoplasms 4Myelodysplastic Syndromes 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Breast Neoplasms 4Brain Neoplasms 4Amyloidosis 4Stomach Neoplasms 3

Interventions

perflutren 1finerenone 1empagliflozin 1Thalidomide 1Eplerenone 1Dexamethasone 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Renal Insufficiency, Chronic × Bortezomib × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡